Episode 77: Revolution Medicines

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Revolution Medicines, the precision oncology company that spent over a decade trying to drug one of cancer’s most notorious targets: RAS. With mutations present in roughly 30% of all new cancer diagnoses, including pancreatic, lung, and colorectal cancers, RAS has long been considered undruggable. Revolution bet their entire company on proving that wrong. We break down the science behind their tricomplex inhibitor platfor...